[1] Musunuru K. Genome editing: the recent history and perspective in cardiovascular diseases[J]. J Am Coll Cardiol, 2017, 70(22): 2808-2821.
[2] Gaj T, Gersbach CA, Barbas CR. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering[J]. Trends Biotechnol,2013, 31(7): 397-405.
[3] Porteus MH. Towards a new era in medicine: therapeutic genome editing[J]. Genome Biol, 2015, 16: 286.
[4] Ishino Y, Shinagawa H, Makino K, et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product[J]. J Bacteriol,1987, 169(12): 5429-5433.
[5] Cao J, Wei J, Yang P, et al. Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance[J]. Mol Cancer, 2018, 17(1): 121.
[6] Albadri S, Bene FD, Revenu C. Genome editing using CRISPR/Cas9-based knock-in approaches in zebrafish[J]. Methods, 2017, 121-122: 77-85.
[7] Bruni GO, Zhong K, Lee SC, et al. CRISPR-Cas9 induces point mutation in the mucormycosis fungus Rhizopus delemar[J]. Fungal Genet Biol, 2019, 124: 1-7.
[8] Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2018, 68(6): 394-424
[9] Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2018, 15(10): 599-616.
[10] Alqahtani A, Khan Z, Alloghbi A, et al. Hepatocellular carcinoma: molecular mechanisms and targeted therapies[J]. Medicina (Kaunas), 2019, 55(9): 526.
[11] Dai ChL, Zhao Y. Comprehension treatment for primary liver cancer[J]. Chinese Journal of Bases and Clinics in General Surgery, 2014, 21(2): 133137.(in Chinese)
戴朝六,赵阳. 原发性肝癌的综合治疗[J]. 中国普外基础与临床杂志, 2014, 21(2): 133-137.
[12] Beck B, Blanpain C. Unravelling cancer stem cell potential[J]. Nat Rev Cancer, 2013, 13(10): 727-738.
[13] Sainz BJ, Heeschen C. Standing out from the crowd: cancer stem cells in hepatocellular carcinoma[J]. Cancer Cell, 2013, 23(4): 431-433.
[14] Chambers I, Colby D, Robertson M, et al. Fucctional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stemcells[J]. Cell, 2003, 113(5): 643-655.
[15] Xu XL, Xing BC, Han HB, et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient’s primary and recurrent tumor[J]. Carcinogenesis, 2010, 31(2): 167-174.
[16] Chu HW, Rios C, Huang C, et al. CRISPR-Cas9-mediated gene knockout in primary human airway epithelial cells reveals a proinflammatory role for MUC18[J]. Gene Ther, 2015, 22(10): 822-829.
[17] An L, Zeng HM, Zheng RSh, et al. Liver cancer epidemiology in China, 2015[J]. Chinese Journal of Oncology, 2019(10): 721-722.(in Chinese)
安澜,曾红梅,郑荣寿,等. 2015年中国肝癌流行情况分析[J]. 中华肿瘤杂志, 2019(10): 721-722.
[18] Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality[J]. J Hepatol, 2017, 67(2): 302-309.
[19] Wang N, Wang S, Li MY, et al. Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies[J]. Ther Adv Med Oncol, 2018, 10: 17588 35918816287.
[20] Zhao W, Wang L, Han H, et al. 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel α2δ1 subunit[J]. Cancer Cell, 2013, 23(4): 541-556.
|